The cardiac ryanodine receptor (RyR2) via mutants of RyR2. It appears increasingly unlikely that a single exclusive common mechanism underlies every case of mutant channel dysfunction, and that each of these potential mechanisms may contribute to the resultant phenotype. The present review will consider very recent mechanistic developments in this field, including new observations from mutant RyR2 transgenic mouse models, peptide-probe studies, and the implications of functional and phenotypic heterogeneity of RyR2 mutations and polymorphisms.
Introduction
A number of malignant arrhythmia syndromes have been linked to mutations in genes encoding cardiac ion channels, providing the opportunity to investigate more precisely the mechanistic basis of particular arrhythmias by studying channel dysfunction [1] . Autosomal dominant mutations in the cardiac ryanodine receptor (RyR2) are predominantly associated with two conditions: CPVT [catecholaminergic polymorphic VT (ventricular tachycardia)] and ARVC/D2 (arrhythmogenic right ventricular cardiomyopathy/dysplasia type 2), both of which present as stress-or exercise-induced VT, which may lead to SCD (sudden cardiac death). As the name implies, ARVC2 is associated with structural abnormalities in the right ventricle wall, and usually presents with arrhythmias of right ventricular origin (reviewed in [2] ), whereas CPVT is characterized by arrhythmogenesis in a structurally normal heart, with a normal resting sinus rhythm and ECG (electrocardiogram) [3] , although some patients have presented with bradycardia [4] .
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There are over 70 human RyR2 mutations discovered so far (see http://www.fsm.it/cardmoc) that are clustered in several discrete regions of the polypeptide, within which appear distinct peaks of mutational frequency (Figure 1) . A similar clustering of mutations in human RyR1 associated with the neuromuscular disorders MH (malignant hyperthermia) and CCD (central core disease) (reviewed in [5] ) suggests that these regions are important for the modulation of channel function.
Arrhythmias associated with ARVD2/CPVT take the form of bidirectional and/or polymorphic VT [6] , which arise from DADs (delayed after-depolarizations), abnormal electrical events caused by increased diastolic SR (sarcoplasmic reticulum) Ca 2+ leak, which in turn activates inward, depolarizing currents via the Na + /Ca 2+ -exchanger [7] . This observation has highlighted the importance of RyR2 in SR Ca 2+ leak and arrhythmogenesis, and has inspired a number of studies (reviewed in greater detail in [8] ) which have made substantial progress towards uncovering the molecular basis of channel dysfunction and how it is triggered and which may also provide a valuable insight into the arrhythmogenic mechanism of RyR2 dysfunction in HF (heart failure). This mini-review discusses some of the more recent findings of these studies.
Phenotypic and functional heterogeneity of RyR2 mutations
The phenotypic manifestation of CPVT is extremely heterogeneous [9] , and there is even a high variability in the symptoms among affected subjects within the same family. This Each residue of RyR2 was scored according to mutational status (0, unmutated; 1, mutated to one different amino acid; 2, mutated to two different amino acids). The mutational index (mean score for each 10-amino-acid window, i.e. residue X+nine downstream residues) was plotted against residue X to provide a graphical representation of the location of mutation-rich regions within the 4967-residue RyR2 polypeptide (for example, for a 10-amino-acid window containing one single mutation and one double mutation, the mutational index = 0.3).
was strikingly demonstrated by d'Amati et al. [10] , where a male carrying the A77V mutation displayed right-ventricle aberrations characteristic of ARVD2, whereas two female relations exhibited stress-induced polymorphic VT in the absence of structural abnormalities, characteristic of CPVT. This could suggest a phenotypic gender bias in mutation carriers (although sample number is very small), and it has been observed that sudden death occurs at a significantly younger age in CPVT/ARVD2-affected males, although the underlying reasons for this are unknown [8] .
Some mutation carriers have been found to be completely asymptomatic, and this variable penetrance has been attributed to environmental and genetic differences between individuals. This idea has recently been further examined, with the discovery that polymorphisms (i.e. base changes commonly found in the general population that are not considered to cause functional abnormalities) may modulate the expression, localization and function of mutant ion channels [11] [12] [13] . This important finding reveals that the heterogeneity in clinical severity characterizing Na + , K + and Ca 2+ channel mutation carriers may be largely due to the 'protection' afforded by incorporation of vital polymorphism containing subunits into the mutant channel structure that can rescue function (or ameliorate dysfunction). On the other hand, the normally benign RyR2 polymorphisms, G1885E and G1886S (∼ 7% occurrence in the population), have been shown to result in SCD, but only when inherited in a composite heterozygous fashion [14] . These results suggest that polymorphisms could also affect mutant channel function. This may be of great significance since these polymorphisms, and therefore potentially other polymorphisms, do not lie in the mutation-rich regions, and so may have been overlooked in genetic screening studies that targeted these mutational 'hot spots'. Accordingly, it is likely that the role of polymorphisms (both negative and potentially positive) in arrhythmias may have so far been undervalued.
Although RyR2 mutations up to now have only been associated with CPVT and ARVD2, recent findings have linked them to two distinct genetic disorders: HCM (hypertrophic cardiomyopathy), a congenital cardiomyopathy resulting in abnormal left ventricular wall thickening [15] , and SIDS (sudden infant death syndrome) arising from sudden increases in sympathetic activity during sleep [16] . Preliminary characterization of an HCM mutation (G2367R) revealed a gain of function even under basal conditions, in contrast with a CPVT mutant characterized in parallel (S2246L), that displayed functional differences to WT (wild-type) only upon activation by PKA (protein kinase A) phosphorylation [15] . This exaggerated functional defect under simulated diastolic conditions was also displayed by a SIDS-linked RyR2 mutant channel (S4565R), although this mutation exhibited comparable Ca 2+ -sensitivity to WT when activated by phosphorylation [16] . In contrast, another SIDS mutation investigated in this study [16] (R2267H) was functionally distinct from WT only after phosphorylation. The demonstration of profound mechanistic differences between mutations that underpin the same disease phenotype is consistent with our observations [17] , and has uncovered functional heterogeneity between ARVC2-linked mutations.
RyR2 phosphorylation as a pathophysiological mechanism: how is it relevant and is it necessarily associated with FKBP12.6 (12.6 kDa FK506-binding protein) dissociation?
The functional modulation of cardiac proteins by phosphorylation is of paramount importance in regulating EC (excitation-contraction) coupling [18] . However, the consequences and significance of RyR2 phosphorylation in myocardial disease pathogenesis continue to be the subject of immense controversy [8] .
The first proposed model of mutation-linked RyR2 dysfunction [19] provided a compelling reconciliation with the hypothesized mechanistic basis of RyR2-dependent SR leak in HF [20] . Wehrens et al. [19] showed that PKA-mediated phosphorylation of RyR2 at Ser 2808 (human residue) resulted in dissociation of the channel-stabilizing protein, FKBP12.6 (later named calstabin2 by these authors), thereby providing a rational explanation for the Ca 2+ leak. Subsequently, they showed that several recombinantly expressed RyR2 mutations (in regions distributed throughout the protein) exhibited a reduced affinity for FKBP12.6 following PKA phosphorylation and thus were characterized by a similar defective regulation [21] .
This hypothesis has since been extrapolated to other pathologies (reviewed in [22] ); however, its validity as a pathogenic mechanism in CPVT has been challenged extensively. Results from diverse experimental systems have shown that neither PKA phosphorylation of the channel at Ser 2808 [23, 24] nor aberrant Ca 2+ release from mutant RyR2 was associated with FKBP12.6 dissociation [25, 26] .
Perhaps the most compelling evidence has come from transgenic mouse models of CPVT/ARVD2 (Table 1) , which display many of the hallmark characteristics of human CPVT, including bidirectional VT (notably absent from FKBP12.6 −/− and FKBP12.6 +/− mice; [19, 27] ). In these RyR2 mutant mice, the interaction of mutant channels with FKBP12.6 was equivalent to that seen in WT mice [28] [29] [30] . Thus dissociation of FKBP12.6 from the RyR2 complex does not appear to be the vital causative event in CPVT pathogenesis, although it may play a role in the more chronic effects of hypertrophy [31] and HF [32] .
The role of channel phosphorylation, however, appears to be more complex. A recent study by Carter et al. [33] suggests that Ser 2808 of RyR2 is phosphorylated to 75% of its full stoichiometry under basal conditions. This phosphostate represents the lowest level of channel activity, and either a modest increase, or substantial reduction, in Ser 2808 phosphorylation results in channel activation by distinct mechanisms. Such a process optimizes functional modulation, since a dramatic change in function could potentially occur due to either a small activity increase in PKA, or channel-associated phosphatase. Alternatively, Ser 2808 phosphorylation may enable RyR2 to become responsive to phosphorylation at other sites, which may be of greater physiological relevance in dynamic channel modulation. In agreement with this, an additional PKA phosphorylation site at Ser 2030 has been proposed as a marker of enhanced β-adrenergic receptor stimulation in cardiac disease models [34] , although there may be further, as yet undiscovered, sites that might also be important. The role of RyR2 phosphorylation is further complicated by the fact that RyR2 is also a substrate for other kinases including CaMKII (Ca 2+ /calmodulindependent protein kinase II), which is known to have a potent effect on RyR2 Ca 2+ release [35] . Indeed, inhibition of CaMKII was recently found to block isoprenaline-induced SR Ca 2+ leak, whereas inhibition of PKA had no effect [36] , signifying that abnormal phosphorylation by CaMKII may be important in arrhythmogenesis. However, difficulties in interpretation arise due to the ability of both these kinases to phosphorylate Ser 2808 [37] . Additionally, it has been shown that CaMKII phosphorylates RyR2 to a 4-fold higher stoichiometry than PKA, suggesting that there are additional CaMKII target sites [38] , one of which has been identified at Ser 2814 [39] . The potential presence of multiple CaMKII sites suggests an even greater range of regulatory control by phosphorylation.
Although the effects of RyR2 phosphorylation in HF have been extensively investigated, comparatively little is known about the relative contribution of these kinases in CPVT pathogenesis. In fact, results from transgenic mouse models and cell systems suggest that differential phosphorylation of RyR2 mutants compared with WT channels does not occur in CPVT (see Table 1 and [25] ). However, of course this does not preclude the possibility that mutant channels are more sensitive to equivalent phosphorylation, as indeed has been implied by recent results from a SIDS-related RyR2 mutation (R2267H) [16] . 2+ -sensitivity was less pronounced in the two N-terminal mutations (R176Q/ T2504M and L433P), indicating a degree of heterogeneity that may be dependent on mutation locus. Interestingly, defective luminal sensing is also implicated in the autosomal recessive form of CPVT caused by mutations in CSQ (calsequestrin) [43] , an RyR accessory protein thought to act as a luminal Ca 2+ sensor [44] . One such mutation is predicted to affect the Ca 2+ buffering ability of this protein (D307H; [43] ), while another is believed to affect the interaction of CSQ with RyR2 and triadin (R33Q; [45, 46] ). Altered luminal Ca 2+ sensing provides a plausible mechanism for aberrant SR Ca 2+ release, which, although distinct from the defective phosphorylation hypothesis discussed above, is predicted to cause similar functional defects. The possibility that RyR2 mutations affect interaction with/regulation by these luminal accessory proteins remains to be investigated.
Sensing the ionic environment: is it
SCD-linked mutation has also been shown to perturb the sensitivity of channel activation by cytosolic Ca 2+ [16, 40, 41] . In particular, Yang et al. [41] demonstrated that peptideinduced disruption of RyR2 (corresponding to the effect of central domain mutation; see section below on interacting domains) lowered the threshold for cytosolic Ca 2+ activation, resulting in sustained SR Ca 2+ leak that could trigger DADs. In addition, sensitized Ca 2+ -dependent activation, such as that induced by low-dose caffeine, has been shown to result in DADs in cardiomyocytes in the presence of β-adrenergic receptor stimulation [47] . This observation suggests that caffeine represents a pharmacomimetic of CPVT, signifying that sensitization to cytosolic Ca 2+ is a potential pathogenic mechanism in arrhythmogenesis. Furthermore, two N-terminal mutations (R176Q/T2504M and L433P) have been shown to exhibit significantly decreased sensitivity to Ca 2+ -dependent channel inhibition [40] , suggesting that mutation may also affect deactivation mechanisms. Although it has been shown that RyR2 mutations can affect both luminal and cytosolic Table 1 Comparison of mutant RyR2 knock-in and FKBP12.6 knockout mice FKBP12.6 −/− and FKBP12.6 +/− mice have been proposed to represent a model of CPVT [19, 27] ; however, RyR2 mutant knock-in models [7, [28] [29] [30] have demonstrated that FKBP12.6 dissociation is unlikely to be a causative mechanism of mutant channel dysfunction. In addition, K201, a proposed anti-arrhythmic drug did not prevent arrhythmogenesis in mice harbouring a RyR2 mutation, although it was completely protective in FKBP12.6 +/− mice. Another FKBP12.6 −/− mouse model has been generated [31] , which, in contrast with the model discussed above, demonstrated hypertrophy and hypertension in male but not female mice. This was attributed to differences in the mouse ES (embryonic stem) cell strain used to generate the model [19] . n.d., not determined.
R176Q [29, 30] R4496C [7, 28] FKBP12.6 −/− [19, 27] FKBP12.6 +/− [27] Mouse strain and ES cells C57BL/6 C57BL/6 C57BL/6 C57BL/6 129Sv/J 129Sv/J DBA/lacJ DBA/lacJ Arrhythmia syndrome ARVD2 CPVT n.d. n.d. Ca 2+ -sensitivity, it is important to note that the interdependent nature of these Ca 2+ environments in living cells means that their effects cannot easily be functionally dissected.
Disruption of interacting domains: a key mechanistic feature of RyR mutation-linked dysfunction?
Discrete regions of RyR1 and RyR2 participate in intramolecular interactions that are believed to stabilize channel conformation, notably between the N-terminus and central domain and the region preceding the TM (transmembrane) domain [48, 49] . In particular, in vitro exposure to a peptide corresponding to a small segment of the RyR2 central domain (residues 2460-2495) results in channel hypersensitization and Ca 2+ leak, caused by presumed competitive binding to the N-terminal domain, thereby disrupting ('unzipping') interaction with the central domain that normally stabilizes the channel. These effects were abolished by introducing a CPVT mutation (R2474S) into the central domain peptide, causing the authors to infer that this mutation results in a structurally unstable RyR2 that is pro-arrhythmogenic [41, 50] . Although it has been suggested that the N-terminal and central domain mutation 'hot spots' directly interact with each other, recent structural findings using GFP (green fluorescent protein) insertion to map SCD-linked mutation sites suggests that Ser 437 lies ∼ 30 Å (1 Å = 0.1 nm) from Ser 2367 in the three-dimensional structure, implying that direct interaction is unlikely [51, 52] . Thus biochemical identification of the RyR2 peptide-binding sites using crosslinking techniques would be invaluable. This was achieved for interacting regions in RyR1 thought to be separated by MH/CCD mutation, whereby interaction between RyR1 residues 4820-4841 (a surface-exposed loop, linking TM domains) and a region of the channel encompassing residues 4114-4142 was established [53] . The equivalent RyR2 peptide (residues 4752-4773) had an activating effect on the channel, which was eliminated by the introduction of a mutation (H4764P; [54] ). Puzzlingly, when present alone, H4764P is not thought to result in an arrhythmic phenotype, although it results in marked arrhythmia susceptibility when found in combination with another nearby mutation (G4662S) [4] , suggesting that the regions critical for interaction in RyR2 may be slightly different from those in RyR1, as is the case for other interacting regions of the channel [55] . Nevertheless, this pre-TM portion of the C-terminus is of functional importance, and is involved in the transduction of regulatory cytoplasmic events to the pore-forming domain [49] . Mutations occurring within this part of the RyR2 (Figure 1) , termed the I-domain (interacting domain; residues 3722-4610), promote post-activation conformational and Ca 2+ release instability, as measured using FRET (fluorescence resonance energy transfer) and Ca 2+ imaging techniques [56] . Domain unzipping may arise due to the conformational instability introduced by RyR2 mutations, which may therefore be a primary mechanistic event in channel dysfunction. Potentially, all the other defects (e.g. altered phosphorylation, co-protein dissociation, and increased sensitivity to Ca 2+ ) could also occur as a result of this conformational instability in RyR2 mutants. Thus it may be surmised that channel dysfunction can arise from defects in various mechanisms that operate within RyR2. This concept is strongly supported by the multi-faceted nature of RyR2 regulation [57] [58] [59] , which provides the background for a broad spectrum of dysfunction that culminates in a common cellular consequence, i.e. DAD generation.
Conclusion
The rate of mutation identification currently surpasses that of their characterization; consequently only ∼ 20% of known mutations have been functionally characterized to date. Studies so far suggest that RyR2 mutations alter the channel's ability to decode its intracellular environment such that CPVT may be considered a disease of 'cellular sensing'. Recent advances have revealed that the basis of channel dysfunction is complex, and imply that the contributory roles of the above-discussed mechanisms should be determined on a mutation-by-mutation basis using animal, cellular and in vitro-based techniques. This methodical approach should ultimately achieve a more comprehensive understanding of the mechanisms of RyR2 dysfunction, in order that more successful anti-arrhythmic treatments can be developed.
Note added in proof (received 10 September 2007)
β-Adrenergic responsiveness was preserved in a recent mouse model in which Ser 2808 was replaced by alanine, implying that phosphorylation at this site does not have a major role in the pathogenesis of cardiac dysfunction [60] . In addition, single channel characterization of recombinant mouse RyR2 has shown that serine-to-alanine mutation at residue 2030, but not at residue 2808, reduced the activating effect of PKA [61] .
